Inhibitors that directly target MT IDH1 and block 2-HG have efficacy in low-grade IDH1 mutant gliomas but have not been proven to be beneficial for mutant high-grade gliomas3–6. The gene discussed is IDH1; the disease is central nervous system cancer.